Table 4.
Treatment Efficacy According to Therapeutic Regimen.
| Regimen/Efficacy | ASV + DCV | GLE/PIB | LDV/SOF ± RBV | OBV/PTV/r ± DSV ± RBV | GZR/EBR | SOF + SMV ± RBV | SOF + RBV | SOF/VEL ± RBV | SOF + DCV ± RBV |
|---|---|---|---|---|---|---|---|---|---|
| SVR ITT, n (%) | 16/19 (84.2) | 209/213 (98.1) | 173/178 (97.2) | 229/233 (98.3) | 152/156 (97.4) | 4/4 (100) | 31/34 (91.2) | 121/124 (97.6) | 2/2 (100) |
| SVR PP, n (%) | 16/17 (94.1) | 209/213 (98.1) | 173/175 (98.9) | 229/232 (98.7) | 152/153 (99.3) | 4/4 (100) | 31/33 (93.9) | 121/123 (98.4) | 2/2 (100) |
ASV: asunaprevir; DCV: daclatasvir; DSV: dasabuvir; EBR: elbasvir; GLE: glecaprevir; GZR: grazoprevir; ITT: intention-to-treat; LDV: ledipasvir; OBV: ombitasvir; PIB: pibrentasvir; PP: Per-protocol; PTV/r: paritaprevir; RBV: ribavirin; SMV: simeprevir; SOF: sofosbuvir; SVR: sustained virologic response; VEL: velpatasvir.